Find out more about which group leaders are recruiting and learn about the eligibility and application process

⚠️ Deadline to apply is Friday 13 February ⚠️

This research represents a big step toward smarter, more precise therapies that could help treat cancers that resist current drugs and allow more patients to live longer, better lives.
Read more about the research here: www.icr.ac.uk/about-us/icr...

When cells divide, their DNA can break. If it’s not repaired, it can lead to cancer. On the flipside, cancer cells often rely on these repair systems to survive. If we block them, cancer cells could die – opening new paths for treatment, such as targeting CIP2A or TOPBP1.

From leading the discovery of investigational drugs like luminespib and pictilisib to laying the groundwork for approved treatments such as capivasertib, Professor Workman has made major contributions to cancer research and treatment.

Read about Paul's achievements ⤵️

www.icr.ac.uk/about-us/icr...

This study shows that men with high levels of chromosomal instability are unlikely to gain extra time from this treatment. A blood test could guide them to better options. This is a big step toward precision oncology, delivering more effective care with less toxicity.

The team identified a marker in cancer cells released into the blood that can reveal whether a key drug, cabazitaxel, is likely to fail. Cabazitaxel is often the go-to chemo when other treatments stop working. But it’s tough on the body, and not everyone benefits.

It’s a step towards more personalised myeloma care – and a reminder that even the smallest genetic differences can make big differences to treatment outcomes.

Read more here ⤵️

www.icr.ac.uk/about-us/icr...

By recreating patient-identified mutations in the lab, the team mapped how each change affects the drug’s ability to bind to a protein called cereblon. Their findings could help clinicians interpret genetic results more precisely and match patients with treatments that are still likely to work.

The research team, led by Dr @charlottepawlyn.bsky.social, and including Dr Yakinthi Chrisochoidou, showed that not all mutations in a certain gene have the same impact, with some blocking older treatments while leaving next-generation therapies effective.

Read the full story here ⬇️